Evidence map›Paper›PMID 34938104›Full record

ArticleInternational journal of general medicine2021

Screening of Breast Cancer Methylation Biomarkers Based on the TCGA Database.

Xuechun Wang, Jia Jia, Xuehong Gu, Wei-Wei Zhao, Caiping Chen, Wanxin Wu, Jiayuan Wang, Midie Xu

Open access · goldAbstract read
In one paragraph

Article in International journal of general medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Deregulated methylation and expression ofFrontiers in immunology · 2025
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xuechun Wang *Department of Laboratory, Jiaxing First Hospital, Jiaxing, 314000, People's Republic of China.
Jia Jia *Shanghai Center for Bioinformation Technology, Shanghai, 201202, People's Republic of China.
Xuehong GuDepartment of Nursing, Jiaxing First Hospital, Jiaxing, 314000, People's Republic of China.
Wei-Wei ZhaoDepartment of Rehabilitation Medicine, Jiaxing First Hospital, Jiaxing, 314000, People's Republic of China.
Caiping ChenDepartment of Breast Surgery, Jiaxing First Hospital, Jiaxing, 314000, People's Republic of China.
Wanxin WuDepartment of Pathology, Jiaxing First Hospital, Jiaxing, 314000, People's Republic of China.
Jiayuan WangDepartment of Laboratory, Jiaxing First Hospital, Jiaxing, 314000, People's Republic of China.
Midie XuDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
First Hospital of Jiaxing · CNFudan University Shanghai Cancer Center · CNShanghai Center For Bioinformation Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveBreast cancer has become a fatal disease for women world-wide. Its incidence in China has been increasing yearly, and the identification of early-stage biomarkers is urgently required.

methodsANOVA was carried out in the case of a primary tumor, adjacent normal tissue, and tumor metastasis of breast cancer, and on pan-cancer samples using the genome-wide methylation data of 31 solid tumor Illumina Methylation 450K chips downloaded from The Cancer Genome Atlas (TCGA) website in September 2018. Methylation sites showing a significant difference (P ≤ 0.05) were screened and compared with the whole-genome methylation data of 31 other solid tumor species in the TCGA database using t-tests in order to screen the methylation sites of breast cancer-specific expression. The expression of the screened methylation sites was confirmed through pyrosequencing in 45 cases of breast cancer, lung cancer, gastric cancer, and colorectal cancer.

resultsA total of 10 specific breast cancer methylation sites (cg13683194, cg07996594, cg21646032, cg07671949, cg21185686, cg03625109, cg16429070, cg23601468, cg24818566, and cg01240931) were analyzed; nine genes (C9orf125, RARB, ESR1, RUNX3, PCDHGB7, DBC1, PDGFRB, TIMP3, and APC) were involved. The overall effect was excellent; a total of 4 methylation sites (2 in the DBC1 gene [cg03625109 and cg24818566], 1 in the C9orf125 gene [cg13683194], and 1 in the PDGFRB gene [cg16429070]) could effectively distinguish breast cancer from 31 other cancer species. The pyrosequencing results revealed that 7 screened methylation sites could significantly distinguish between breast cancer, lung cancer, gastric cancer, and colorectal cancer samples; these sites could also specifically distinguish between luminal A, luminal B, HER2, and Basal-like types of breast cancer.

conclusionThe 10 breast cancer methylation sites screened in the present study can effectively distinguish breast cancer from 31 other solid tumors, and they are expected to be used as biomarkers for early screening of breast cancer.

Indexed as

ANOVABasal-like breast cancerbiomarkerbreast cancermethylationTCGA

Identifiers

PMID34938104
PMCPMC8687519
OpenAlexW4200127596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.